{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:50:59Z","timestamp":1793901059821,"version":"4.8.0"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"8","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R00HL098692"],"award-info":[{"award-number":["R00HL098692"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32HL092332"],"award-info":[{"award-number":["T32HL092332"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01 CA094237"],"award-info":[{"award-number":["P01 CA094237"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor\u2013modified T cells (CAR T cells) produce proinflammatory cytokines that increase expression of T-cell checkpoint signals such as PD-L1, which may inhibit their functionality against solid tumors. In this study, we evaluated in human tumor xenograft models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad (HDAd) that expresses a PD-L1 blocking mini-antibody (mini-body; HDPDL1) as a strategy to enhance CAR T-cell killing. Coadministration of these agents (CAd-VECPDL1) exhibited oncolytic effects with production of PD-L1 mini-body locally at the tumor site. On their own, HDPDL1 exhibited no antitumor effect and CAd-VECPDL1 alone reduced tumors only to volumes comparable to Onc.Ad treatment. However, combining CAd-VECPDL1 with HER2.CAR T cells enhanced antitumor activity compared with treatment with either HER2.CAR T cells alone or HER2.CAR T cells plus Onc.Ad. The benefits of locally produced PD-L1 mini-body by CAd-VECPDL1 could not be replicated by infusion of anti-PD-L1 IgG plus HER2.CAR T cells and coadministration of Onc.Ad in an HER2+ prostate cancer xenograft model. Overall, our data document the superiority of local production of PD-L1 mini-body by CAd-VECPDL1 combined with administration of tumor-directed CAR T cells to control the growth of solid tumors. Cancer Res; 77(8); 2040\u201351. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-16-1577","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T20:40:19Z","timestamp":1487968819000},"page":"2040-2051","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":210,"title":["Armed Oncolytic Adenovirus\u2013Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors"],"prefix":"10.1158","volume":"77","author":[{"given":"Kiyonori","family":"Tanoue","sequence":"first","affiliation":[{"name":"1Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Rosewell Shaw","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Porter","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhakti","family":"Rana","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas."},{"name":"3Department of Pediatrics, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Brenner","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas."},{"name":"3Department of Pediatrics, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,4,13]]},"reference":[{"key":"2022061706173107900_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2022061706173107900_bib2","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/jvi.67.10.5911-5921.1993","article-title":"Packaging capacity and stability of human adenovirus type 5 vectors","volume":"67","author":"Bett","year":"1993","journal-title":"J Virol"},{"key":"2022061706173107900_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-398342-8.00008-2","article-title":"Chapter eight\u2013Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans","volume":"115","author":"Cerullo","year":"2012","journal-title":"Adv Cancer Res"},{"key":"2022061706173107900_bib4","first-page":"14008","article-title":"Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy","volume":"1","author":"Farzad","year":"2014","journal-title":"Mol Ther"},{"key":"2022061706173107900_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2022061706173107900_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR\u2013T-cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Ann Rev Med"},{"key":"2022061706173107900_bib7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"2022061706173107900_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022061706173107900_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2022061706173107900_bib10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti\u2013PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2022061706173107900_bib11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022061706173107900_bib12","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"2022061706173107900_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase IA study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022061706173107900_bib14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/mt.2012.277","article-title":"Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo","volume":"21","author":"Suzuki","year":"2013","journal-title":"Mol Ther"},{"key":"2022061706173107900_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1089\/hum.2009.096","article-title":"Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories","volume":"21","author":"Suzuki","year":"2010","journal-title":"Hum Gene Ther"},{"key":"2022061706173107900_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"2022061706173107900_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/CJI.0b013e318165f5d2","article-title":"Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale","volume":"31","author":"Kaka","year":"2008","journal-title":"J Immunother"},{"key":"2022061706173107900_bib18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2022061706173107900_bib19","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706173107900_bib20","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/nprot.2009.171","article-title":"Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice","volume":"4","author":"Kim","year":"2009","journal-title":"Nat Protocols"},{"key":"2022061706173107900_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T-cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"2022061706173107900_bib22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2022061706173107900_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-15-3130","article-title":"CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination","author":"Ahrends","year":"2016","journal-title":"Cancer Res"},{"key":"2022061706173107900_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2022061706173107900_bib25","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1101\/gad.1441306","article-title":"Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes","volume":"20","author":"Lih","year":"2006","journal-title":"Gen Devel"},{"key":"2022061706173107900_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2022061706173107900_bib27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"2022061706173107900_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2022061706173107900_bib29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2022061706173107900_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"Gill","year":"2015","journal-title":"Immunol Rev"},{"key":"2022061706173107900_bib31","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"2022061706173107900_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1477-2574.2011.00344.x","article-title":"Engineered T cells for pancreatic cancer treatment","volume":"13","author":"Katari","year":"2011","journal-title":"HPB"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/8\/2040\/2763315\/2040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/8\/2040\/2763315\/2040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:06:00Z","timestamp":1655474760000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/77\/8\/2040\/625046\/Armed-Oncolytic-Adenovirus-Expressing-PD-L1-Mini"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,13]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,4,13]]},"published-print":{"date-parts":[[2017,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-16-1577","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22416083.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416068","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416059","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416065","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416059.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416077","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416074.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416083","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416071","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416077.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416074","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416062","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416071.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416080","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416080.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6509453","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6509453.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416062.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416068.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416065.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,13]]}}}